Sourcing Bacteriostatic Water in the US and Canada: Prescription Status, Distributors and Mislabelled Saline

In the United States, bacteriostatic water for injection is a prescription drug: the approved labelling is an "Rx only" document, and the legitimately marketed 30 mL vials trace back to a single approved application, NDA 018802 ^[1][2]. In Canada, the identical article is not a prescription drug. Health Canada's Drug Product Database lists BACTERIOSTATIC WATER FOR INJECTION USP under DIN 00038202, held by Pfizer Canada ULC, status Marketed, schedule "Ethical" ^[3] — a defined category meaning a product that, under federal legislation, does not require a prescription but is generally prescribed by a practitioner ^[4]. That asymmetry drives most of what follows: who may legally hold the product, what paperwork travels with it, and what turns up in the box when neither applies.

This is procurement and product-authenticity material, written for someone acquiring a compendial diluent as laboratory stock. What follows is where the article legitimately originates, which public registers confirm it, and the documented ways in which what arrives is not what the invoice said.

Is bacteriostatic water prescription-only in the United States?

Federally, yes. The FDA-approved labelling describes a sterile, nonpyrogenic preparation of water for injection with benzyl alcohol added at 0.9% (9 mg/mL) or 1.1% (11 mg/mL) as a bacteriostatic preservative, supplied in a 30 mL multiple-dose vial, and it carries two statements that matter for sourcing as much as for handling: "FOR DRUG DILUENT USE ONLY" and "WARNING: NOT FOR USE IN NEONATES" ^[1]. The reference presentation is NDC 0409-3977-03 from Hospira, Inc. ^[1][2].

Prescription status is not a formality — it determines who may lawfully move the product. Under the Drug Supply Chain Security Act, prescription drugs travel between authorised trading partners: manufacturers, repackagers, wholesale distributors and dispensers, each of which must satisfy the statutory conditions before the next may transact with it ^[6]. Wholesale distributors and third-party logistics providers must be appropriately licensed and must report that licensure to FDA annually to hold the status at all ^[5]. A seller operating outside that chain — no licence, no transaction documentation, no dispenser at the end of it — is not a distributor in the regulatory sense of the word, whatever the website header says.

Why Canada classifies it differently, and what "Ethical" means

"Ethical" is a defined term in the Drug Product Database, not a euphemism. Health Canada's terminology page describes it as a product that, in accordance with federal legislation, does not require a prescription but that is generally prescribed by a medical practitioner — the same bucket that holds contrast agents and haemodialysis solutions. The line separating "Ethical" from "Prescription" is the Prescription Drug List: an Ethical product's medicinal ingredient is not on it ^[4].

Two cautions follow. The database records federal status only: provincial scheduling and an individual pharmacy's policy are separate questions it does not answer, and a pharmacist may decline for reasons unrelated to the DIN. And federal status says nothing about who may import or wholesale the article. That is the Drug Establishment Licence regime, under which a Canadian entity in the chain — most often the importer — must hold a DEL covering fabrication, packaging and labelling, testing, importation, distribution or wholesale, with foreign sites appearing on the importer's licence rather than holding one themselves ^[8].

Who manufactures it, and what the word "distributor" hides

Query the National Drug Code Directory for this brand name and a pattern appears immediately. Most finished-product listings are not separate manufacturers: they are repackagers and relabellers — a medical supply house, a procurement company, a distribution firm — each carrying its own NDC and each pointing back to the same application number, NDA 018802 ^[2]. There is far less manufacturing diversity here than the number of brands on a shelf implies. That is not a defect; it is what one approved article distributed through many hands looks like. It does mean the useful question about a seller is never "who makes it" but "which application number does the listing cite".

The same query returns the counter-example. At least one listing branded as bacteriostatic water, in 30 mL multiple-dose vials twenty-five to a carton from a labeler registered outside North America, carries the marketing category "unapproved drug other" and no application number at all ^[2]. It is in the directory. It has an NDC. It is not an approved drug. FDA states the point without hedging: inclusion does not indicate that the agency verified the information, and assignment of an NDC does not in any way denote approval ^[2].

A third lane exists and is routinely misdescribed in sales copy. Outsourcing facilities registered under section 503B may compound sterile products, but registration means only that FDA received the information required to register — not that the facility produces FDA-approved drugs, and not that it complies with current good manufacturing practice. Drugs made by compounders, outsourcing facilities included, are not FDA-approved and have not undergone premarket review ^[7]. Material from a 503B facility may be perfectly appropriate stock; it is simply a different regulatory object from an NDA product, and a certificate that blurs the two is itself a finding.

How to verify a supplier before money moves

• Read the NDC or DIN off the vial rather than off the listing page, then look it up. In the US, check the Marketing Category column and treat a blank or "unapproved drug other" entry as your answer ^[2]. In Canada, the Drug Product Database entry should read Marketed ^[3].
• Match the application number. A repackager's own NDC should still resolve to the originating application; a finished-product listing with none is not an approved article ^[2].
• Check the seller, not only the product. A US wholesale distributor must be licensed and must report that licensure to FDA annually, so a firm absent from both state records and the federal annual report is not an authorised trading partner ^[5][6].
• In Canada, search the drug and health products inspections database, which replaced the former establishment licence live listing and is searchable by company, site, licensing status and inspection date ^[9].
• Search FDA's warning letter database for the trading name and the domain — public, free, and for this commodity unusually productive ^[10].
• Ask for lot-specific documentation and confirm the lot on the certificate matches the lot printed on the vial that arrived. A document naming no lot is a marketing sheet; one that names it also commits the issuer to the identity, assay and method entries printed beside it, which are worth reading rather than filing.

Why sellers of research compounds get warning letters over water

Across late 2025 and 2026 FDA issued a run of warning letters to websites selling research peptides, following a recognisable template: the agency reviewed the site over a stated period, lists the products offered, and concludes they are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act. What is instructive for a buyer is that bacteriostatic water appears in those product lists in its own right, named alongside the peptides ^[10]. The reasoning is that offering a lyophilised compound and its reconstitution diluent together evidences the intended use of both.

Two consequences point the same way. A research-use disclaimer does not alter the analysis, because intended use is read from the whole presentation of an offer rather than from a footer. And a diluent bundled into a peptide order has, by construction, arrived outside the pharmaceutical distribution chain — the provenance problem and the regulatory problem seen from two angles. Sourcing the diluent separately, from a supplier whose licensure resolves in a public register, addresses both.

Be plain about what this evidence is. Warning letters are enforcement records: they establish the agency's stated position and that named sellers were offering named products. They are not experimental data and not a prevalence measurement. No published survey exists of how often diluent sold through informal channels is out of specification, mislabelled or non-sterile — the analyses that have been run on vials bought outside the licensed chain tested the compounds rather than the water sent with them — so any failure rate quoted for this market is a number nobody has measured. The defensible response is procedural rather than statistical — prefer a source verifiable in a register, because the alternative is unmeasured rather than measured and found acceptable.

Bacteriostatic water versus mislabelled sodium chloride

Four compendial articles circulate under names that careless listings collapse into one, and two of the four are preserved. Bacteriostatic 0.9% Sodium Chloride Injection, USP contains sodium chloride at 9 mg/mL and benzyl alcohol at 9 mg/mL, has a label pH of 5.0 within a range of 4.5 to 7.0, and comes in 10, 20 and 30 mL multiple-dose vials under NDC 0409-1966 ^[11]. Its indication sentence and its "NOT FOR USE IN NEONATES" warning are word for word what appears on the water label ^[1][11]. The cartons resemble each other, the vials resemble each other, and the only dependable difference is the article name.

The substitution matters at the bench for a mundane reason: one diluent is a near-neutral aqueous vehicle, the other a concentrated ionic solution labelled at a calculated osmolarity of 308 mOsmol per litre, with sodium and chloride each at 154 mEq per litre ^[12]. Swapping one for the other silently changes the ionic strength of everything prepared from it and breaks comparability across a series, even in the common case where nothing visible happens. Which vehicle suits a given compound is a solvent-selection question answered against that compound's own solubility behaviour, not one to be settled by whichever carton a distributor picked off the shelf.

The physical check is trivial and worth owning outright. Water for injection is held to a conductivity ceiling — USP General Chapter <645> sets the Stage 1 limit at 1.3 µS/cm at 25 °C, and both packaged water articles are made from that water ^[13]. Benzyl alcohol is non-ionic and barely moves the reading, while a 0.9% sodium chloride solution sits in the millisiemens-per-centimetre range, roughly four orders of magnitude higher. A pocket conductivity meter therefore separates a water-based diluent from a saline-based one in seconds, with no chemistry and no consumables. What it cannot do is confirm that a preservative is present or at what concentration; that needs an assay, which in practice means relying on the certificate — exactly why the certificate has to come from a source you checked.

• The full article name. "BAC water" is not an article name; "Bacteriostatic Water for Injection, USP" is, and the difference is the whole point.
• A quantitative statement of preservative content. Canadian regulations require the outer label of a parenteral drug to carry a quantitative list of any preservatives present ^[14]; the approved US labelling gives benzyl alcohol as a percentage and in mg/mL ^[1].
• A lot number and expiry printed or embossed into the label, not stickered over something else.
• A named manufacturer with a physical address and an identifier that resolves in the relevant register ^[2][3].
• The neonate warning and the diluent-use-only statement — both on the approved labelling, neither reliably reproduced by a relabeller ^[1].

These are pharmacopoeially defined articles whose attributes are stated, testable and traceable to a monograph and an application number — which is what makes them useful as laboratory reference diluents, and what a substitute cannot offer. The material discussed here, and the research compounds these diluents are used with in a laboratory setting, are supplied for research use only. They are not medicinal products, they are not intended for administration to humans or animals, and nothing above is guidance for anything beyond handling laboratory stock and the records that accompany it.